AstraZeneca Plans Largest Manufacturing Investment In Virginia

AstraZeneca has chosen Virginia for its largest single manufacturing facility investment as part of a broader plan to invest $50 billion in the United States by 2030. The announcement was made by Virginia Governor Glenn Youngkin alongside AstraZeneca CEO Pascal Soriot and White House National Economic Council Director Kevin Hassett, highlighting the project's role in advancing pharmaceutical manufacturing technology and strengthening the domestic supply chain. The investment is expected to create hundreds of highly skilled jobs and support AstraZeneca's goal of reaching $80 billion in revenue by 2030. Virginia officials emphasized the state's growing reputation as a hub for life sciences innovation, supported by its top-tier research institutions and skilled workforce. AstraZeneca's commitment reflects confidence in America's biopharmaceutical innovation and aims to benefit patients both domestically and globally. This facility will mark the company's largest global manufacturing investment to date.